Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACON CRC randomised controlled trial.

JB, Trouiller; B, Macabeo; A, Poll; D, Howard; A, Buckland; M, Sivignon; E, Clay; D, Malka; E, Samalin; M, Toumi; P, Laramée

doi:10.1136/bmjopen-2022-063700

Public

Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACON CRC randomised controlled trial.

Shared by NobleBlocks on Nov 21, 2022 • 12:00 AM UTC

Authors:

Trouiller JB

Macabeo B

Poll A

Abstract

Objective The BEACON CRC randomised controlled trial (NCT02928224) in BRAF-mutant metastatic colorectal cancer (mCRC) patients showed improved overall survival for the combination treatment of encorafenib (BRAF inhibitor) with cetuximab (EGFR inhibitor) compared with cetuximab with chemotherapy (FOL...

Subject

Health Economics

Gastrointestinal Tumours

Adult Oncology

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!